{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:09:57Z","timestamp":1795108197942,"version":"4.10.3"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5+DM) is associated with poor prognosis and high mortality, presenting significant challenges for treating this intractable disease. This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective observational study, MDA5+DM patients from the First Affiliated Hospital of Zhengzhou University between August 2019 and June 2024 were included. Patients were categorized into three groups according to the different immunosuppressive regimens. One-year mortality and the potential risk factors for death was analyzed using the Kaplan-Meier survival analysis and Cox proportional hazards regression, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 152 patients were divided into CNI group(n=49, 32.2%), CNI+TOF group(n=52, 34.2%), and CNI+CTX group(n=51, 33.6%). The 1-year survival rate was significantly lower in the CNI group compared to in the combination therapy groups (logrank P = 0.032). However, the CNI+CTX group showed a higher overall infection rate compared to CNI and CNI+TOF group (51.0% vs 28.6% vs 32.7%, p=0.048). Multivariate analysis identified combination therapy and higher CD8+ T cells act as protective factors, whereas co-infection is a major predictor of mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1658547","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:28:24Z","timestamp":1763360904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Congcong","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaohui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103264","DOI":"10.1016\/j.autrev.2022.103264","article-title":"The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review","volume":"22","author":"Grazzini","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"Ida","year":"2023","journal-title":"RMD Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac450","article-title":"Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China","volume":"62","author":"You","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"151959","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review","volume":"53","author":"McPherson","year":"2022","journal-title":"Semin Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11926-025-01188-7","article-title":"Anti- melanoma differentiation-associated gene 5 antibody positive dermatomyositis: recent progress in pathophysiology and treatment","volume":"27","author":"Yoshida","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/jmpuxa","article-title":"Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study","volume":"43","author":"You","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15274","article-title":"Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"47","author":"Matsuda","year":"2020","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.40320","article-title":"2017 european league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, amsterdam, the Netherlands, 14\u201316 december 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","article-title":"High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center","volume":"23","author":"Huang","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S460702","article-title":"Prevalence, risk factors, and mortality of invasive pulmonary aspergillosis in patients with anti-MDA5+ Dermatomyositis: A retrospective study in China","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflammation Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead063","article-title":"High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis","volume":"62","author":"Chen","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead034","article-title":"Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5","volume":"62","author":"Liu","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa266","article-title":"The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease","volume":"59","author":"Huang","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.13607","article-title":"Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis","volume":"293","author":"Jin","year":"2023","journal-title":"J Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.42264","article-title":"Two distinct immune cell signatures predict the clinical outcomes in patients with amyopathic dermatomyositis with interstitial lung disease","volume":"74","author":"Ye","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/e51d3m","article-title":"Expansion of exhausted CD8+ T cells associates with increased pulmonary fungal infection risk in anti-melanoma differentiation associated gene 5 dermatomyositis","volume":"42","author":"Xu","year":"2024","journal-title":"Clin Exp Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:28:26Z","timestamp":1763360906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2025.1658547"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658547","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1658547"}}